Overview
Amar Gupta is a General Surgeon in Dallas, Texas. Dr. Gupta is rated as a Distinguished provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Liver Failure, Progressive Familial Intrahepatic Cholestasis Type 1, Progressive Familial Intrahepatic Cholestasis Type 2, Liver Transplant, and Simultaneous Pancreas Kidney Transplant. Dr. Gupta is currently accepting new patients.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- HMO
- POS
- MANAGED MEDICAID PLAN
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
3600 Gaston Ave, Suite 656, Dallas, TX 75246
University Of Texas Southwestern Medical Center At Dallas
Adam Yopp is a Surgical Oncologist and a General Surgeon in Dallas, Texas. Dr. Yopp is rated as an Elite provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Liver Cancer, Adrenocortical Carcinoma, Adrenal Cancer, Hepatectomy, and Pancreaticoduodenectomy.
MedHealth
Dhiresh Jeyarajah is a General Surgeon in Richardson, Texas. Dr. Jeyarajah has been practicing medicine for over 36 years and is rated as an Elite provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Hiatal Hernia, Hernia, Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
University Of Texas Southwestern Medical Center At Dallas
Matthew Porembka is a Surgical Oncologist and a General Surgeon in Dallas, Texas. Dr. Porembka is rated as a Distinguished provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Stomach Cancer, Pancreatic Cancer, Gastroesophageal Junction Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Liver FailureDr. Gupta isDistinguished. Learn about Liver Failure.
- Progressive Familial Intrahepatic Cholestasis Type 1
- Progressive Familial Intrahepatic Cholestasis Type 2
- Progressive Familial Intrahepatic Cholestasis Type 3
- Advanced
- Cholangiocarcinoma (Bile Duct Cancer)
- Familial Pancreatic CancerDr. Gupta isAdvanced. Learn about Familial Pancreatic Cancer.
- Fibrolamellar CarcinomaDr. Gupta isAdvanced. Learn about Fibrolamellar Carcinoma.
- Experienced
- Bile Duct StrictureDr. Gupta isExperienced. Learn about Bile Duct Stricture.
- Caroli DiseaseDr. Gupta isExperienced. Learn about Caroli Disease.
- CholangitisDr. Gupta isExperienced. Learn about Cholangitis.
- CholedocholithiasisDr. Gupta isExperienced. Learn about Choledocholithiasis.
- CholestasisDr. Gupta isExperienced. Learn about Cholestasis.
- Chronic Antibody-Mediated RejectionDr. Gupta isExperienced. Learn about Chronic Antibody-Mediated Rejection.